IBKS No2 SPAC
GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disea… Read more
IBKS No2 SPAC (204840) - Total Liabilities
Latest total liabilities as of September 2025: ₩26.45 Billion KRW
Based on the latest financial reports, IBKS No2 SPAC (204840) has total liabilities worth ₩26.45 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
IBKS No2 SPAC - Total Liabilities Trend (2015–2024)
This chart illustrates how IBKS No2 SPAC's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
IBKS No2 SPAC Competitors by Total Liabilities
The table below lists competitors of IBKS No2 SPAC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Allied Telesis Holdings K.K
OTCGREY:ATSKF
|
USA | $25.56 Billion |
|
Western Uranium & Vanadium Corp
OTCQX:WSTRF
|
USA | $4.11 Million |
|
Nanexa AB
ST:NANEXA
|
Sweden | Skr36.61 Million |
|
Wanshih Electronic Co Ltd
TWO:6134
|
Taiwan | NT$997.63 Million |
|
PlayD Co. Ltd
KQ:237820
|
Korea | ₩50.95 Billion |
|
Indonesia Energy
NYSE MKT:INDO
|
USA | $3.28 Million |
|
Atari S.A.
PA:ALATA
|
France | €92.30 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down IBKS No2 SPAC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IBKS No2 SPAC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IBKS No2 SPAC (2015–2024)
The table below shows the annual total liabilities of IBKS No2 SPAC from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩22.77 Billion | -17.45% |
| 2023-12-31 | ₩27.59 Billion | +11.40% |
| 2022-12-31 | ₩24.76 Billion | +64.59% |
| 2021-12-31 | ₩15.05 Billion | -27.07% |
| 2020-12-31 | ₩20.63 Billion | -14.70% |
| 2019-12-31 | ₩24.19 Billion | +1.86% |
| 2018-12-31 | ₩23.74 Billion | +161.34% |
| 2017-12-31 | ₩9.09 Billion | +140.17% |
| 2016-12-31 | ₩3.78 Billion | -33.42% |
| 2015-12-31 | ₩5.68 Billion | -- |